{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:42:19Z","timestamp":1793400139557,"version":"4.5.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Although follicular lymphoma (FL) is usually graded as FL1-2, FL3A, and FL3B, some borderline cases can be observed and led us to investigate the clinicopathologic diversity of grade 3 FL (FL3). Among 2449 FL patients enrolled in Lymphoma Study Association (LYSA) trials, 1921 cases with sufficient material underwent a central pathologic review. The resulting diagnoses comprised 89.6% FL1-2 (n=1723), 7.2% FL3A (n=138), and 0.5% purely follicular FL3B (n=9). The remaining 51 unclassifiable cases (2.7%) exhibited high-grade features but did not meet WHO criteria for either FL3A or FL3B; and were considered as \u201cunconventional\u201d high-grade FL (FL3U). FL3U morphological pattern consisted of nodular proliferation of large cleaved cells or small-sized to medium-sized blast cells. Compared with FL3A, FL3U exhibited higher MUM1 and Ki67 expression, less <jats:italic toggle=\"yes\">BCL2<\/jats:italic> breaks and more <jats:italic toggle=\"yes\">BCL6<\/jats:italic> rearrangements, together with a higher number of cases without any <jats:italic toggle=\"yes\">BCL2<\/jats:italic>, <jats:italic toggle=\"yes\">BCL6<\/jats:italic> or <jats:italic toggle=\"yes\">MYC<\/jats:italic> rearrangement. FL3U harbored less frequent mutations in <jats:italic toggle=\"yes\">BCL2<\/jats:italic>, <jats:italic toggle=\"yes\">KMT2D<\/jats:italic>, <jats:italic toggle=\"yes\">KMT2B<\/jats:italic>, and <jats:italic toggle=\"yes\">CREBBP<\/jats:italic> than FL3A. <jats:italic toggle=\"yes\">MYC<\/jats:italic> and <jats:italic toggle=\"yes\">BCL2<\/jats:italic> were less frequently mutated in FL3U than FL3B. Rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone treated FL3U patients had a worse survival than FL1-2 patients with similar follicular lymphoma international prognostic index and treatment. These results suggest that high-grade FLs encompass a heterogeneous spectrum of tumors with variable morphology and genomic alterations, including FL3U cases that do not strictly fit WHO criteria for either FL3A or FL3B, and display a worse outcome than FL1-2. The distinction of FL3U may be useful to allow a better comprehension of high-grade FLs and to design clinical trials.<\/jats:p>","DOI":"10.1097\/pas.0000000000001726","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T03:02:52Z","timestamp":1627873372000},"page":"1324-1336","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B"],"prefix":"10.1097","volume":"45","author":[{"given":"Camille","family":"Laurent","sequence":"first","affiliation":[{"name":"Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse"},{"name":"INSERM, U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, laboratoire d\u2019excellence TOUCAN, Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ad\u00e9la\u00efde","sequence":"additional","affiliation":[{"name":"Predictive Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Guille","sequence":"additional","affiliation":[{"name":"Predictive Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Tesson","sequence":"additional","affiliation":[{"name":"Institut Carnot CALYM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Gat","sequence":"additional","affiliation":[{"name":"Institut Carnot CALYM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solene","family":"Evrard","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Escudi\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Syrykh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Canioni","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Necker"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Department of Pathology, AP-HP, H\u00f4pital Saint-Antoine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Meignin","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Saint-Louis, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chassagne-Clement","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre L\u00e9on B\u00e9rard"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Dartigues","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Gustave Roussy, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Hospitalier Lyon-Sud"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Parrens","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, H\u00f4pital du Haut L\u00e9v\u00eaque, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huet","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d\u2019H\u00e9matologie, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[{"name":"LYSA-P, H\u00f4pital Henri Mondor, Creteil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Research Center of Lyon, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Birnbaum","sequence":"additional","affiliation":[{"name":"Predictive Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Brousset","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse"},{"name":"INSERM, U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, laboratoire d\u2019excellence TOUCAN, Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"University Lille, CHU Lille, ULR 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es (GRITA), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"Pathology and Tumor Immunology, Institut Paoli-Calmettes, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Aix-Marseille University, Marseille"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.3324\/haematol.2017.175059","article-title":"Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort","volume":"103","author":"Rimsza","year":"2018","journal-title":"Haematologica"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.clml.2017.06.006","article-title":"Rituximab improves the outcome of patients with grade 3 follicular lymphoma receiving anthracycline-based therapy","volume":"17","author":"Yuan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3324\/haematol.12754","article-title":"Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas","volume":"93","author":"Piccaluga","year":"2008","journal-title":"Haematologica"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3324\/haematol.2017.181024","article-title":"Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2","volume":"103","author":"Horn","year":"2018","journal-title":"Haematologica"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","article-title":"Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL","volume":"27","author":"Koch","year":"2016","journal-title":"Ann Oncol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2017.07.002","article-title":"Grade 3 follicular lymphoma: outcomes in the rituximab era","volume":"17","author":"Mustafa Ali","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.humpath.2017.11.002","article-title":"Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma","volume":"72","author":"El Behery","year":"2018","journal-title":"Hum Pathol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900010209","article-title":"Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method","volume":"1","author":"Mann","year":"1983","journal-title":"Hematol Oncol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood.V68.4.837.837","article-title":"What should be the morphologic criteria for the subdivision of follicular lymphomas?","volume":"68","author":"Nathwani","year":"1986","journal-title":"Blood"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2559.2005.02068.x","article-title":"Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology","volume":"46","author":"Leoncini","year":"2005","journal-title":"Histopathology"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00428-015-1864-y","article-title":"The heterogeneity of follicular lymphomas: from early development to transformation","volume":"468","author":"Xerri","year":"2016","journal-title":"Virchows Arch"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.2008.16.4061","article-title":"Comparison of referring and final pathology for patients with non-Hodgkin\u2019s lymphoma in the National Comprehensive Cancer Network","volume":"26","author":"LaCasce","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2014.04.008","article-title":"Follicular lymphoma grade 3: review and updates","volume":"14","author":"Vaidyanathan","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"R22-20250608","first-page":"190","article-title":"Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1-3 DLBCL patients (<60 years): third planned interim and final analyses of the gained trial","volume":"626","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2010.038109","article-title":"Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA","volume":"96","author":"Fitoussi","year":"2011","journal-title":"Haematologica"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A Phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-07-2536","article-title":"Integrated profiling of basal and luminal breast cancers","volume":"67","author":"Adelaide","year":"2007","journal-title":"Cancer Res"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","article-title":"Circular binary segmentation for the analysis of array-based DNA copy number data","volume":"5","author":"Olshen","year":"2004","journal-title":"Biostatistics"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/bloodadvances.2016000786","article-title":"Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets","volume":"1","author":"Bolen","year":"2017","journal-title":"Blood Adv"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.humpath.2014.06.019","article-title":"Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis","volume":"45","author":"Xerri","year":"2014","journal-title":"Hum Pathol"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2006-09-045989","article-title":"CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features","volume":"109","author":"Karube","year":"2007","journal-title":"Blood"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00428-017-2152-9","article-title":"B-cell lymphomas with discordance between pathological features and clinical behavior","volume":"471","author":"de Leval","year":"2017","journal-title":"Virchows Arch"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/modpathol.2017.134","article-title":"Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements","volume":"31","author":"Miyaoka","year":"2018","journal-title":"Mod Pathol"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.humpath.2016.07.025","article-title":"Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature","volume":"58","author":"Miao","year":"2016","journal-title":"Hum Pathol"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"key":"R45-20250608","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"R47-20250608","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"key":"R48-20250608","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/pin.12335","article-title":"Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements","volume":"65","author":"Yoshida","year":"2015","journal-title":"Pathol Int"},{"key":"R49-20250608","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"R50-20250608","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R51-20250608","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"R52-20250608","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjh.13502","article-title":"Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy","volume":"172","author":"Mercadal","year":"2016","journal-title":"Br J Haematol"},{"key":"R53-20250608","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.humpath.2013.06.013","article-title":"Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy","volume":"44","author":"Maeshima","year":"2013","journal-title":"Hum Pathol"},{"key":"R54-20250608","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3960\/jslrt.53.121","article-title":"Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma","volume":"53","author":"Tomita","year":"2013","journal-title":"J Clin Exp Hematop"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:05:34Z","timestamp":1749416734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001726","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}